TME Pharma NV: A Focus on Innovative Cancer Therapies

TME Pharma NV, a clinical-stage pharmaceutical company, is making strides in the biotechnology sector with its focus on developing novel therapies for glioblastoma and pancreatic cancer. Operating under the Health Care sector and listed on the Frankfurt Stock Exchange, the company is headquartered in Berlin and serves a global customer base.

As of April 23, 2025, TME Pharma NV’s stock closed at 0.0612 EUR. The company’s market capitalization stands at 6,120,000 EUR. Over the past year, the stock has experienced significant volatility, with a 52-week high of 0.2755 EUR on June 3, 2024, and a low of 0.000078 EUR on December 3, 2024. The price-to-earnings ratio is currently at -0.112075, reflecting the company’s ongoing development phase and lack of profitability.

TME Pharma NV is dedicated to addressing the urgent need for effective treatments in oncology, particularly for glioblastoma and pancreatic cancer, two of the most challenging cancers to treat. The company’s commitment to innovation and patient care positions it as a key player in the global biotechnology landscape.

As TME Pharma NV continues its clinical trials and research efforts, stakeholders and investors are closely monitoring its progress in bringing new therapies to market. The company’s strategic focus on these critical areas of cancer treatment underscores its potential to make significant contributions to healthcare and patient outcomes worldwide.